Answer
Tepotinib is indicated to treat adults with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 skipping alterations.
Sources for this answer
- Tepotinib 225 mg film-coated tabletsMerck · emc · SmPC §4.1 Therapeutic Indications · Version 2Document updated
Sources checked